To examine patterns of long-term PrEP adherence and its association with HIV seroconversion in NSW, Australia. Population-based HIV PrEP implementation study. EPIC-NSW was an open-label study of daily oral PrEP which recruited participants from March 2016 to April 2018. Adherence was measured using dispensing records. PrEP discontinuation was defined as a ≥120-day period without PrEP coverage. Long-term adherence patterns were identified using group-based trajectory modelling. Participants dispensed at least once (n = 9586) were almost all male (98.5%), identified as gay (91.3%), with a median age of 34 years (range 18-86). Of the 6460 (67.4%) participants who had at least nine-months of follow-up since first dispensing, 1942 (30.1%) discontinued. Among these, 292 (15.0%) restarted later. Four distinct groups were identified ('Steep decline' in adherence (15.8%), 'Steady decline' (11.6%), 'Good adherence' (37.4%), and 'Excellent adherence' (35.2%)). Older (p < 0.001) and gay-identified (p < 0.001) participants were more likely to have higher adherence, so were those living in postcodes with a higher proportion of gay-identified male residents (p < 0.001). Conversely, those who at baseline reported recent crystal methamphetamine use and had a recent diagnosis of sexually transmitted infection (STI) had lower adherence (p < 0.001). Overall HIV incidence was 0.94 per 1000 person-years (95%CI 0.49-1.81; n = 9) and was highest in the 'steep decline' group (5.45 per 1000 person-years; p = 0.001). About 15% of participants stopped PrEP during study follow-up and were at increased risk of HIV infection. They were more likely to be younger and report a recent STI or methamphetamine use prior to PrEP initiation. About 15% of participants stopped PrEP during study follow-up and were at increased risk of HIV infection. They were more likely to be younger and report a recent STI or methamphetamine use prior to PrEP initiation. Our study's primary objective was to compare 1-year survival rates between serum cryptococcal antigen (sCrAg)-positive and sCrAg-negative HIV-positive individuals with CD4 counts <100 cells/μl without symptoms of meningitis in Zimbabwe. This was a prospective cohort study. Participants were enrolled as either sCrAg-positive or sCrAg-negative and followed up for ≤52 weeks, with death as the outcome. Lumbar punctures (LPs) were recommended to all sCrAg-positives and inpatient management with intravenous amphotericin B and high-dose fluconazole was recommended to those with disseminated Cryptococcus. Antiretroviral therapy was initiated immediately in sCrAg-negatives and after ≥4 weeks following initiation of antifungals in sCrAg-positives. Multivariable logistic regression models were used to determine risk factors for mortality. We enrolled 1320 participants and 130 (9.8%) were sCrAg positive, with a median sCrAg titre of 120. Sixty-six (50.8%) sCrAg-positives had LPs and 16.7% (11/66) had central nHD package, hence it should always be part of the comprehensive clinical evaluation in AHD patients. Untreated HIV infection was previously associated with IL-32 overexpression in gut epithelial cells (IEC). Here, we explored IL-32 isoform expression in the colon of people living with HIV (PLWH) receiving antiretroviral therapy (ART) and IL-32 triggers/modulators in IEC. Sigmoid colon biopsies (SCB) and blood were collected from ART-treated PLWH (HIV + ART; n = 17; mean age 56 years; CD4 counts 679 cells/μl; time on ART 72 months) and age-matched HIV-uninfected controls (HIVneg; n = 5). The IEC line HT-29 was used for mechanistic studies. Cells from SCB and blood were isolated by enzymatic digestion and/or gradient centrifugation. HT-29 cells were exposed to TLR1-9 agonists, TNF-α, IL-17A, and HIV. IL-32α/β/γ/D/ε/θ and IL-17A mRNA levels were quantified by real-time RT-PCR. IL-32 protein levels were quantified by ELISA. IL-32β/γ/ε isoform transcripts were detectable in the blood and SCB, with IL-32β mRNA levels being predominantly expressed in both compartments and at significantly higher levels in HIV + ART compared to HIVneg. IL-17A transcripts were only detectable in SCB, with increased IL-17A levels in HIVneg compared to HIV + ART and negatively correlated with IL-32β mRNA levels. IL-32β/γ/ε isoform mRNA were detected in HT-29 cells upon exposure to TNF-α, Poly IC (TLR3 agonist), Flagellin (TLR-5 agonist) and HIV. IL-17A significantly decreased both IL-32 β/γ/ε mRNA and cell-associated IL-32 protein levels induced upon TNF-α and Poly IC triggering. We document IL-32 isoforms abundant in the colon of ART-treated PLWH and reveal the capacity of the Th17 hallmark cytokine IL-17A to attenuate IL-32 overexpression in a model of inflamed IEC. We document IL-32 isoforms abundant in the colon of ART-treated PLWH and reveal the capacity of the Th17 hallmark cytokine IL-17A to attenuate IL-32 overexpression in a model of inflamed IEC. anal condylomas are associated with human papillomavirus (HPV) infection and are a risk factor for anal squamous cell carcinoma (SCC). to conduct a meta-analysis evaluating the prevalence of anal high-risk-HPV, high-grade squamous intraepithelial lesions (HSIL) and SCC in patients with condylomas. https://www.selleckchem.com/products/foxy5.html The standardised incidence ratio (SIR) and the incidence rate (IR) of anal SCC were also calculated. three electronic databases were searched until April 2020. Meta-analyses were performed using random effects models. pooled prevalence estimate of HR-HPV in anal condylomas was 40.2% (21.0 - 63.1) in immunocompromised and 16.4% (10.7 - 24.3) in non-immunocompromised patients, with an odds ratio (OR) of 3.79 (1.51-9.52, P = 0.005) for immunocompromised patients. HR-HPV in condylomas with HSIL was 73.8% (39.1 - 92.5) and in non-HSIL cases was 17.7% (9.6 - 30.2), corresponding to an OR of 12.33 (2.97-51.21, P = 0.001) for those with HSIL. The prevalence of HSIL in condylomas was 24.0% (16.4 - 33.7) in immunocompromised and 11.8% (7.2 - 18.8) in non-immunocompromised patients, with an OR of 2.51 (1.72-3.65, P < 0.001) for immunocompromised patients. The overall prevalence of anal SCC was 0.3% (0.0 - 1.7). The SIR of anal SCC was 10.7 (8.5 - 13.5), 20.1 (14.4 - 28.2) in men and 7.7 (5.6 - 10.5) in women. The overall IR of anal SCC was 6.5 per 100 000 persons-year (3.6 - 11.7), 12.7 (9.1 - 17.8) in men and 4.7 (1.7 - 13) in women. patients with a history of anal condylomas have a high risk of anal SCC, especially men. The prevalence of HR-HPV and HSIL in condylomas from immunocompromised patients is high. This information can change patient follow-up and treatment. patients with a history of anal condylomas have a high risk of anal SCC, especially men. The prevalence of HR-HPV and HSIL in condylomas from immunocompromised patients is high. This information can change patient follow-up and treatment.